Adding two blood–borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early stage disease, a research team from The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

The trio of biomarkers, tested in three separate cohorts, including two blinded validation studies, improved the detection of patients with early stage disease compared to healthy or benign disease controls.

“Adding these two biomarkers provided statistically significant improvement for all early stage cancer versus healthy controls as well as other subcohorts when used with the current gold standard biomarker, CA 19–9,” said Ann Killary, PhD, professor of Translational Molecular Pathology.

At early stages, pancreatic cancer can be successfully removed with surgery, but 80 percent of patients are diagnosed with either locally advanced disease (stage III) or cancer that has spread to other organs (stage IV), when surgery is no longer a curative option.

Pancreatic cancer is the fourth–leading cause of deaths from cancer in the United States, with an estimated 53,070 new cases diagnosed in 2016 and 41,780 deaths, according to the National Cancer Institute.

“Our goal is to identify more patients at those earlier, resectable stages, when treatment could lead to a five year survival rate of 30 percent or more, depending on stage,” Killary said. Only about 7 percent of patients survive for five years following diagnosis of the disease.

Additional studies in larger cohorts will be needed to validate these findings, and more biomarkers will be needed to get the completely accurate set needed to screen the general population with the long term goal of identifying precursor lesions before they become malignant.

In the current study, deploying TFPI and an isoform of tenascin C, TNC–FN IIIC, with CA 19–9 improved performance discriminating stage I and II disease from healthy or benign disease controls.

The principal measure of efficacy is called Area Under the Curve (AUC), a measure of how well biomarkers identify true cases of disease (sensitivity) while avoiding false positives (specificity). A perfect AUC would have a score of 1.0.

Any biomarker test for the general public will need to be close to a perfect 1.0, Killary noted, given the infrequency of pancreatic cancer in the population at large. In the group’s analysis of three cohorts of samples, AUC scores for the combination consistently outscored CA–19–9 alone.

For the first cohort of samples, comparing stage I/IIA and healthy controls yielded an AUC of 0.72 for CA–19–9 alone compared to 0.84 for the combination. For stage IIB vs. controls, the combination raised CA–19–9’s performance from an AUC of 0.87 to 0.98. The second blinded cohort also showed improvements in AUC over CA19–9.

A third, larger blinded validation study of 252 samples of cases and controls from the Early Detection Research Network of the National Cancer Institute further confirmed those findings and also permitted the team to measure the trio’s ability to detect disease in patients without a history of pancreatitis or diabetes. The AUC for those patients was 0.87 for Stage I/IIA, 0.93 for Stage IIB and 0.89 for all early stages of the disease using the combination, pointing to a potential ability to detect disease in those who lack either of those known risk–raising conditions.

Killary said the team is working to use the biomarkers in MD Anderson’s high–risk clinic, established through MD Anderson’s Pancreatic Cancer Moon Shot™, part of the institution’s Moon Shots Program™ to accelerate the development of life–saving advances based on scientific discovery.